Dear Shareholder,

 

Sinovac is uniquely positioned as the only vaccine company that is both headquartered in China and listed on the American Stock Exchange.  We are very pleased with our track record that has lead to the discovery, development and commercialization of three vaccines to protect against infectious diseases.  We have continued to advance our robust development pipeline that consists of an Avian Flu-Pandemic Influenza vaccine, a Japanese Encephalitis vaccine and a SARS vaccine.  We are the first and only company in the world to have successfully completed a Phase I trial for the SARS indication. 

 

Our fully integrated operating strategy has enabled us to both develop and commercialize our products.  We have two state of the art research and manufacturing facilities in China that span nearly 10,000 square meters.  Our established sales force has strong relationships with municipal and provincial CDC’s along with coverage of over 25 provinces in China.  We have entered into strategic collaborations with distribution partners to bring our vaccines to targeted markets such as South America and Southeast Asia. 

 

With our innovative product offering and integrated business model, our strategy is to become a leading global biopharmaceutical company focused on the development and commercialization of vaccines that address the unmet need of protecting against infectious diseases.  On behalf of management and all Sinovac employees, we would like to thank our shareholders for their continued support and look forward to continuing to deliver shareholder value as we execute our growth strategy. 

 

Sincerely,

Yin Weidong

President and CEO